The aim of our study is to measure the level of awareness, preconceptions, and level of fear regarding epidural analgesia among childbearing women in KKUH in Riyadh.

开始日期2022-08-01

申办/合作机构

King Khalid University Hospital

[+1]

NCT04716439 / Unknown statusN/AIIT

Effect of Total Intravenous Anesthesia (TIVA) With Magnesium Sulfate on Intra-Operative Neuromonitoring (IONM) in Patients Undergoing Spine Surgery

Anesthesia for neurosurgery requires balancing deep and effective anesthesia as well as postoperative analgesia versus the risks of delayed recovery and postoperative respiratory depression. This randomized placebo-controlled, double-blind study was designed to evaluate the effect of magnesium sulfate on the total anesthetic and analgesic consumption using the clinical parameters in addition to the effect on IONM reading.

开始日期2021-02-01

申办/合作机构

King Khalid University Hospital

NCT04680923 / CompletedN/AIIT

Efficacy of Combined Periportal and Preperitoneal Local Anesthetic Infiltration (CPPLAI) in Laparoscopic Sleeve Gastrectomy Patients

The high demand for bariatric surgery due to the increasing prevalence of obesity worldwide necessitate evidence-based clinical pathway such as Enhanced Recovery After Bariatric Surgery (ERABS). The paradigm of surgery has been shifted from open to laparoscopic in morbidly obese patients. Laparoscopic Sleeve Gastrectomy (LSG) is the most common procedure performed in our institute for sustained weight loss and amelioration of obesity-related comorbidities. Pain control in ERABS is one of the key factors for improved outcomes. Surgery induced acute postoperative pain, stress response and fatigue lead to prolonged convalescence and hospital stay. Optimal titrated safe postoperative pain management in LSG patients still remains a challenge.

开始日期2020-12-08

申办/合作机构

King Khalid University Hospital

100 项与 King Khalid University Hospital 相关的临床结果

登录后查看更多信息

0 项与 King Khalid University Hospital 相关的专利（医药）

登录后查看更多信息

1,872

项与 King Khalid University Hospital 相关的文献（医药）

2024-12-01·Radiology Case Reports

Placement of transurethral urinary drainage catheter using microwire in a newborn with posterior urethral valve: A better alternative to suprapubic catheterization

Article

作者: Alzeer, Meshari A. ; Alzeer, Meshari A ; Alhuqayl, Fawaz S ; Alkhayatt, Ahmad M ; Alkhayatt, Ahmad M. ; Alsaikhan, Naif ; Alhuqayl, Fawaz S.

Posterior urethral valves (PUV) present significant challenges in neonatal urinary management, often indicating the use of a suprapubic catheter (SPC). However, complications associated with SPC, coupled with specific contraindications call for alternative approaches. Here, we present a case of successful transurethral catheterization in a 1-day-old premature male infant with PUV, utilizing bedside Ultrasound without anesthesia, effectively alleviating the need for a SPC. The procedure involved careful wire insertion and subsequent catheter placement, facilitating urine drainage, and enabling a micturating cystourethrogram (MCUG) using the same access point. By avoiding SPC-related risks and allowing for essential diagnostic procedures, this approach presents itself as a less invasive and possibly better initial option, particularly in cases where SPC may pose complications. Our findings suggest that ultrasound-guided transurethral catheterization offers a minimally invasive and effective alternative to SPC, proving its potential to enhance patient care and outcomes in challenging PUV cases.

2024-09-13·Medicine

Lack of association of ABO and RhD blood groups with COVID-19 mortality: A 2-center cross-sectional study in Saudi Arabia

Article

作者: Malak, Hesham A. ; Jalal, Naif A. ; Alhamoud, Abdullah H. ; Alqarni, Abdulaziz H. ; Al Eissa, Mariam M. ; Kabrah, Saeed M. ; Daowd, Rateb A. ; Bantun, Farkad ; Halawani, Amr J. ; Alshahrani, Musaed M. ; Khan, Anmar A. ; Mujalli, Abdulrahman ; Algarni, Ateeg M.

Several diseases, including both noninfectious diseases and bacterial and viral diseases, are associated with the ABO and RH blood group systems. Previous studies have shown a link between blood type and the probability of coronavirus disease 2019 (COVID-19) infection. In this study, we aimed to explore the correlation between deaths caused by COVID-19 and ABO and RhD blood types in Saudi Arabia. In this cross-sectional observational study, data from COVID-19 patients were collected from 2 major hospitals treating COVID-19 in Riyadh City, Saudi Arabia, between March 2020 and November 2021. The association between ABO and RhD blood types and COVID-19 outcomes was investigated. A total of 2302 real-time polymerase chain reaction-confirmed COVID-19 patients were enrolled in this study; a chi-square test was used to determine the statistical significance of the data. Of the 2302 enrolled patients, 1008 (43.8%) had blood type O, 677 (29.41%) had blood type A, 502 (21.8%) had blood type B, and 115 (5%) had blood type AB. Of the patients, 2143 (93.1%) were RhD-positive. The O-positive blood type had the highest mortality rate among COVID-19-infected patients, whereas the AB-negative type had the lowest. However, statistical analysis revealed no significant correlation between blood type (ABO or RhD) and COVID-19-based susceptibility or mortality. In conclusion, we found no association between ABO and RhD blood types and either susceptibility to or mortality due to COVID-19 in Saudi Arabia.

2024-09-06·Medicine

Use and effectiveness of PCSK-9 inhibitors in heart diseases: A review.

Review

作者: Alayoubi, Fakhr Z ; El Hajj, Maguy Saffouh ; Alayoubi, Samha ; Ibrahim, Nihal Abdalla ; Harbi, Maan H ; Alorfi, Nasser M

Proprotein Convertase Subtilisin/Kexin type-9 (PCSK-9) inhibitors have recently used in the management of different cardiac complications. Several clinical trials demonstrated their effectiveness in patients with hypercholesterolemia. However, the effectiveness of these medications in patients with heart diseases is still controversial. To review and summarize the clinical trials pertaining to the use and effectiveness of PCSK-9 inhibitors in heart diseases and to discuss the pharmacotherapy of these agents. A review was conducted of all clinical trials with PCSK-9 inhibitors for heart diseases registered at ClinicalTrials.gov since inception up to and including January 19th, 2024. These trials were retrieved. Data from these trials were extracted manually, categorized and analyzed. The number of identified clinical trials was 25,371. After screening and excluding irrelevant studies, 12 studies met the search criteria. The majority of these studies were conducted in the US. The total number of patients in these studies was 27,700. Alirocumab and Evolocumab were the most frequently used PCSK-9 inhibitors. This review identified only a few clinical trials on PCSK-9 inhibitors in heart disease patients. Therefore, it is recommended to conduct more randomized controlled clinical trials on PCSK-9 inhibitors in this patient population.

100 项与 King Khalid University Hospital 相关的药物交易

登录后查看更多信息

100 项与 King Khalid University Hospital 相关的转化医学

登录后查看更多信息